ArticleCancer biology & therapy2014
Targeting of two aspects of metabolism in breast cancer treatment.
Article in Cancer biology & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- Trial
- Targeting CAF-specific metabolic pathways in breast cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma.International journal of cancer · 2023Article
- An examination of variables associated with breast cancer early detection behaviors of women.African health sciences · 2022Article
- The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer.Cancer metastasis reviews · 2021Review
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.Journal for immunotherapy of cancer · 2021Article
- Article
- Dichloroacetate Radiosensitizes Hypoxic Breast Cancer Cells.International journal of molecular sciences · 2020Article
- HIFs, angiogenesis, and metabolism: elusive enemies in breast cancer.The Journal of clinical investigation · 2020Review
- Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer.Cancers · 2020Review
- The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas.Oncotarget · 2020Article
- Lactate Metabolism and Immune Modulation in Breast Cancer: A Focused Review on Triple Negative Breast Tumors.Frontiers in oncology · 2020Review
- Article
- Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.Oncotarget · 2018Article
- Long-term stabilization of metastatic melanoma with sodium dichloroacetate.World journal of clinical oncology · 2017Article
- Pyruvate dehydrogenase expression is negatively associated with cell stemness and worse clinical outcome in prostate cancers.Oncotarget · 2017Article
- Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.Journal of the American Society of Nephrology : JASN · 2016Article
- Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy.World journal of clinical cases · 2016Article
- PDK2-mediated alternative splicing switches Bnip3 from cell death to cell survival.The Journal of cell biology · 2015Article
- Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implication.World journal of biological chemistry · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deregulated metabolism is gaining recognition as a hallmark of cancer cells, and is being explored for therapeutic potential. The Warburg effect is a metabolic phenotype that occurs in 90% of tumors, where glycolysis is favored despite the presence of oxygen. Dichloroacetate (DCA) is a pyruvate dehydrogenase kinase (PDK) inhibitor that can reverse the Warburg effect. PENAO (4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid) is a novel anti-mitochondrial agent that targets the adenine nucleotide transporter in mitochondria and is currently in clinical trials for solid tumors. We have investigated the targeting of two aspects of metabolism, using DCA to promote mitochondrial activity combined with PENAO to inhibit mitochondrial activity, in breast and other carcinoma cell lines. PENAO was effective at low uM concentrations in luminal (T-47D) and triple negative (MDA-MB-231) breast cancer cells, in normoxia and hypoxia. The cytotoxicity of PENAO was enhanced by DCA by a mechanism involving increased reactive oxygen species in both T-47D and MDA-MB-231 cells, however further investigations found it did not always involve PDK2 inhibition or reduction of the mitochondrial membrane potential, which are the accepted mechanisms for DCA induction of apoptosis. Nevertheless, DCA sensitized all cancer cell lines tested toward apoptosis of PENAO. DCA and PENAO are both currently in clinical trials and targeting cancer metabolism with these drugs may offer options for difficult to treat cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.